INDIANAPOLIS, Ind. (ADAMS) – COVID-19 antibody therapies developed at Indianapolis-based Eli Lilly have been paused.
The U.S. Department of Health and Human Services says the therapies are unlikely to be effective against the Omicron variant.
The therapies from Eli Lilly were given Emergency Use Authorization to treat COVID-19 in February. It was expanded earlier this month to treat pediatric patients.
Read more here
